Molecular Markers In The Diagnosis Of Thyroid Nodules [marcadores Moleculares No Diagnóstico De Nódulos Tireoidianos]

An indeterminate thyroid nodule cytology result occurs about every sixth fine-needle aspiration. These indeterminate nodules harbor a 24% risk of malignancy (ROM); too high to ignore, but driving surgery where most nodules are benign. Molecular diagnostics have emerged to ideally avoid surgery when appropriate, and to trigger the correct therapeutic surgery when indicated, as opposed to an incomplete diagnostic surgery. No current molecular test offers both high sensitivity and high specificity. A molecular diagnostic test with high sensitivity (e.g. Afirma Gene Expression Classifier sensitivity 90%) offers a high Negative Predictive Value when the ROM is relatively low, such as < 30%. Only such tests can "rule-out" cancer. In this setting, a molecularly benign result suggests the same ROM as that of operated cytologically benign nodules (~6%). Thus, clinical observation can replace diagnostic surgery; increasing quality of life and decreasing medical costs. However, its low specificity cannot "rule-in" cancer as a suspicious result has a Positive Predictive Value (PPV) of ~40%, perhaps too low to routinely reflex to definitive cancer surgery. Conversely, high specificity tests (BRAF, RAS, PPAR/PAX-8, RET/PTC, PTEN) offer high PPV results, and only these tests can "rule-in" cancer. Here a positive molecular result warrants definitive therapeutic surgery. However, their low sensitivity cannot "rule-out" cancer and a negative molecular result cannot dissuade diagnostic surgery; limiting their cost-effectiveness. Whether or not there is a useful and cost-effective role to sequentially combine these approaches, or to modify existing approaches, is under investigation. © ABE&M todos os direitos reservados.5728997Cooper, D.S., Doherty, G.M., Haugen, B.R., Kloos, R.T., Lee, S.L., Mandel, S.J., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer (2009) Thyroid, 19 (11), pp. 1167-1214Hegedus, L., Clinical practice.The thyroid nodule (2004) N Engl J Med, 351 (17), pp. 1764-1771Melillo, R.M., Santoro, M., Molecular biomarkers in thyroid FNA samples (2012) J Clin Endocrinol Metab, 97 (12), pp. 4370-4373Wang, C.C., Friedman, L., Kennedy, G.C., Wang, H., Kebebew, E., Steward, D.L., A large multicenter correlation study of thyroid nodule cytopathology and histopathology (2011) Thyroid, 21 (3), pp. 243-251Bryson, P.C., Shores, C.G., Hart, C., Thorne, L., Patel, M.R., Richey, L., Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas (2008) Arch Otolaryngol Head Neck Surg, 134 (6), pp. 581-586Saravanan, P., Chau, W.F., Roberts, N., Vedhara, K., Greenwood, R., Dayan, C.M., Psychological well-being in patients on "adequate" doses of l-thyroxine: Results of a large, controlled community-based questionnaire study (2002) Clin Endocrinol (Oxf), 57 (5), pp. 577-585Cooper, D.S., Biondi, B., Subclinical thyroid disease (2012) Lancet, 379 (9821), pp. 1142-1154Shrime, M.G., Goldstein, D.P., Seaberg, R.M., Sawka, A.M., Rotstein, L., Freeman, J.L., Cost-effective management of low-risk papillary thyroid carcinoma (2007) Arch Otolaryngol Head Neck Surg, 133 (12), pp. 1245-1253Esnaola, N.F., Cantor, S.B., Sherman, S.I., Lee, J.E., Evans, D.B., Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis (2001) Surgery, 130 (6), pp. 921-930Hundahl, S.A., Cady, B., Cunningham, M.P., Mazzaferri, E., McKee, R.F., Rosai, J., Initial results from a prospective cohort study of 5,583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study (2000) Cancer, 89 (1), pp. 202-217Bergenfelz, A., Jansson, S., Kristoffersson, A., Martensson, H., Reihner, E., Wallin, G., Complications to thyroid surgery: Results as reported in a database from a multicenter audit comprising 3,660 patients (2008) Langenbecks Arch Surg, 393 (5), pp. 667-673Ernandes-Neto, M., Tagliarini, J.V., Lopez, B.E., Padovani, C.R., Marques Mde, A., Castilho, E.C., Factors influencing thyroidectomy complications (2012) Braz J Otorhinolaryngol, 78 (3), pp. 63-69Sosa, J.A., Bowman, H.M., Tielsch, J.M., Powe, N.R., Gordon, T.A., Udelsman, R., The importance of surgeon experience for clinical and economic outcomes from thyroidectomy (1998) Ann Surg, 228 (3), pp. 320-330Saunders, B.D., Wainess, R.M., Dimick, J.B., Doherty, G.M., Upchurch, G.R., Gauger, P.G., Who Performs Endocrine Operations In the United States? (2003) Surgery, 134 (6), pp. 924-931. , discussion 931Gonzalez-Sanchez, C., Franch-Arcas, G., Gomez-Alonso, A., Morbidity following thyroid surgery: Does surgeon volume matter? (2012) Langenbecks Arch Surg, , Nov 6Borget, I., Vielh, P., Leboulleux, S., Allyn, M., Iacobelli, S., Schlumberger, M., Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules (2008) Am J Clin Pathol, 129 (5), pp. 763-771Renshaw, A., An estimate of risk of malignancy for a benign diagnosis in thyroid fine-needle aspirates (2010) Cancer Cytopathol, 118 (4), pp. 190-195Lewis, C.M., Chang, K.P., Pitman, M., Faquin, W.C., Randolph, G.W., Thyroid fine-needle aspiration biopsy: Variability in reporting (2009) Thyroid, 19 (7), pp. 717-723Shrestha, M., Crothers, B.A., Burch, H.B., The impact of thyroid nodule size on the risk of malignancy and accuracy of fine-needle aspiration: A 10-year study from a single institution (2012) Thyroid, 22 (12), pp. 1251-1256Alexander, E.K., Kennedy, G.C., Baloch, Z.W., Cibas, E.S., Chudova, D., Diggans, J., Preoperative diagnosis of benign thyroid nodules with indeterminate cytology (2012) N Engl J Med, 367, pp. 705-715Marchevsky, A.M., Walts, A.E., Bose, S., Gupta, R., Fan, X., Frishberg, D., Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies (2010) Diagn Cytopathol, 38 (4), pp. 252-259Davies, L., Welch, H.G., Thyroid cancer survival in the United States: Observational data from 1973 to 2005 (2010) Arch Otolaryngol Head Neck Surg, 136 (5), pp. 440-444Ito, Y., Miyauchi, A., Inoue, H., Fukushima, M., Kihara, M., Higashiyama, T., An observational trial for papillary thyroid microcarcinoma in Japanese patients (2010) World J Surg, 34 (1), pp. 28-35Renshaw, A.A., Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: Distinct patterns and associated risk of malignancy (2011) Cancer Cytopathol, 119 (5), pp. 322-327Piana, S., Frasoldati, A., Ferrari, M., Valcavi, R., Froio, E., Barbieri, V., Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate?Experience of over 18,000 FNAs reported at the same institution during 1998-2007 (2011) Cytopathology, 22 (3), pp. 164-173Cibas, E.S., Ali, S.Z., The Bethesda System for Reporting Thyroid Cytopathology (2009) Thyroid, 19 (11), pp. 1159-1165Walts, A.E., Bose, S., Fan, X., Frishberg, D., Scharre, K., de Peralta-Venturina, M., A simplified Bethesda System for reporting thyroid cytopathology using only four categories improves intra- and in- ter-observer diagnostic agreement and provides non-overlapping estimates of malignancy risks (2012) Diagn Cytopathol, 40 (SUPPL. 1), pp. E62-E68Vanderlaan, P.A., Marqusee, E., Krane, J.F., Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: Should repeated fna be the preferred initial approach? (2011) Am J Clin Pathol, 135 (5), pp. 770-775Bongiovanni, M., Krane, J.F., Cibas, E.S., Faquin, W.C., The atypical thyroid fine-needle aspiration: Past, present, and future (2012) Cancer Cytopathol, 120 (2), pp. 73-86Faquin, W.C., Baloch, Z.W., Fine-needle aspiration of follicular patterned lesions of the thyroid: Diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations (2010) Diagn Cytopathol, 38 (10), pp. 731-739Renshaw, A.A., Does a repeated benign aspirate change the risk of malignancy after an initial atypical thyroid fine-needle aspiration? (2010) Am J Clin Pathol, 134 (5), pp. 788-792Na, D.G., Kim, J.H., Sung, J.Y., Baek, J.H., Jung, K.C., Lee, H., Coreneedle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology (2012) Thyroid, 22 (5), pp. 468-475de Matos, P.S., Ferreira, A.P., de Oliveira Facuri, F., Assumpcao, L.V., Metze, K., Ward, L.S., Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy (2005) Histopathology, 47 (4), pp. 391-401Kim, M.I., Alexander, E.K., Diagnostic use of molecular markers in the evaluation of thyroid nodules (2012) Endocr Pract, 18 (5), pp. 796-802Lodewijk, L., Prins, A.M., Kist, J.W., Valk, G.D., Kranenburg, O., Rinkes, I.H., The value of miRNA in diagnosing thyroid cancer: A systematic review (2012) Cancer Biomark, 11 (6), pp. 229-238Dettmer, M., Vogetseder, A., Durso, M.B., Moch, H., Komminoth, P., Perren, A., MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas (2013) J Clin Endocrinol Metab, 98 (1), pp. E1-E7Kleiman, D.A., Sporn, M.J., Beninato, T., Crowley, M.J., Nguyen, A., Uccelli, A., Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: A prospective case series of 960 patients (2012) Cancer, , Dec 21Nikiforov, Y.E., Ohori, N.P., Hodak, S.P., Carty, S.E., Lebeau, S.O., Ferris, R.L., Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples (2011) J Clin Endocrinol Metab, 96 (11), pp. 3390-3397Ferraz, C., Eszlinger, M., Paschke, R., Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules (2011) J Clin Endocrinol Metab, 96 (7), pp. 2016-2026Yip, L., Farris, C., Kabaker, A.S., Hodak, S.P., Nikiforova, M.N., McCoy, K.L., Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies (2012) J Clin Endocrinol Metab, 97 (6), pp. 1905-1912Jameson, J.L., Minimizing unnecessary surgery for thyroid nodules (2012) N Engl J Med, 367 (8), pp. 765-767NCCN Clinical Practice Guidelines in Oncology (2013) Thyroid Carcinoma, , http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf, Available, Accessed on: Jan 9Walsh, P.S., Wilde, J.I., Tom, E.Y., Reynolds, J.D., Chen, D.C., Chudova, D.I., Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules (2012) J Clin Endocrinol Metab, 97 (12), pp. E2297-E2306Chudova, D., Wilde, J.I., Wang, E.T., Wang, H., Rabbee, N., Egidio, C.M., Molecular classification of thyroid nodules using high-dimensionality genomic data (2010) J Clin Endocrinol Metab, 95 (12), pp. 5296-5304Lew, J.I., Snyder, R.A., Sanchez, Y.M., Solorzano, C.C., Fine needle aspiration of the thyroid: Correlation with final histopathology in a surgical series of 797 patients (2011) J Am Coll Surg, 213 (1), pp. 188-194. , discussion 194-85Papaparaskeva, K., Nagel, H., Droese, M., Cytologic diagnosis of medullary carcinoma of the thyroid gland (2000) Diagn Cytopathol, 22 (6), pp. 351-358Shah, S.S., Faquin, W.C., Izquierdo, R., Khurana, K.K., FNA of misclassified primary malignant neoplasms of the thyroid: Impact on clinical management (2009) Cytojournal, 6, p. 1Jo, V.Y., Stelow, E.B., Dustin, S.M., Hanley, K.Z., Malignancy risk for fineneedle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology (2010) Am J Clin Pathol, 134 (3), pp. 450-456Choi, N., Moon, W.J., Lee, J.H., Baek, J.H., Kim, D.W., Park, S.W., Ultrasonographic findings of medullary thyroid cancer: Differences according to tumor size and correlation with fine needle aspiration results (2011) Acta Radiol, 52 (3), pp. 312-316Bugalho, M.J., Santos, J.R., Sobrinho, L., Preoperative diagnosis of medullary thyroid carcinoma: Fine needle aspiration cytology as compared with serum calcitonin measurement (2005) J Surg Oncol, 91 (1), pp. 56-60Kudo, T., Miyauchi, A., Ito, Y., Takamura, Y., Amino, N., Hirokawa, M., Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens (2007) Thyroid, 17 (7), pp. 635-638Dustin, S.M., Jo, V.Y., Hanley, K.Z., Stelow, E.B., High sensitivity and positive predictive value of fine-needle aspiration for uncommon thyroid malignancies (2012) Diagn Cytopathol, 40 (5), pp. 416-421Elisei, R., Bottici, V., Luchetti, F., Di Coscio, G., Romei, C., Grasso, L., Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders (2004) J Clin Endocrinol Metab, 89 (1), pp. 163-168Fischer, A.H., Clayton, A.C., Bentz, J.S., Wasserman, P.G., Henry, M.R., Souers, R.J., Performance differences between conventional smears and liquid-based preparations of thyroid fineneedle aspiration samples: Analysis of 47,076 responses in the College of American Pathologists Interlaboratory Comparison Program in Non-Gynecologic Cytology (2013) Arch Pathol Lab Med, 137 (1), pp. 26-31Kloos, R.T., O'Reilly, K., Traweek, S.T., Alexander, E.K., Harrell, R.M., Haugen, B.R., (2012) Novel Gene Expression Classifier Raises Pre-operative Suspicion of Medullary Thyroid Cancer (abstract). AACE 21st Annual Scientific and Clinical Congress, , Philadelphia, PACostante, G., Durante, C., Francis, Z., Schlumberger, M., Filetti, S., Determination of calcitonin levels in C-cell disease: Clinical interest and potential pitfalls (2009) Nat Clin Pract Endocrinol Metab, 5 (1), pp. 35-44Kloos, R.T., Eng, C., Evans, D.B., Francis, G.L., Gagel, R.F., Gharib, H., Medullary thyroid cancer: Management guidelines of the American Thyroid Association (2009) Thyroid, 19 (6), pp. 565-612Duick, D.S., Klopper, J.P., Diggans, J.C., Friedman, L., Kennedy, G.C., Lanman, R.B., The Impact of Benign Gene Expression Classifier Test Results on the Endocrinologist-Patient Decision to Operate on Patients with Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytopathology (2012) Thyroid, , Jul 11Li, H., Robinson, K.A., Anton, B., Saldanha, I.J., Ladenson, P.W., Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules (2011) J Clin Endocrinol Metab, 96 (11), pp. E1719-E1726Yassa, L., Cibas, E.S., Benson, C.B., Frates, M.C., Doubilet, P.M., Gawande, A.A., Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation (2007) Cancer, 111 (6), pp. 508-51

Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer

10.1530/ERC-14-0537Endocrine-Related Cancer222121-13

Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone.

OBJECTIVES: To evaluate the diagnostic accuracy of fine-needle aspiration biopsy (FNAB) to preoperatively diagnose medullary thyroid cancer (MTC) among multiple international centers and evaluate how the cytological diagnosis alone could impact patient management. METHODS: We performed a retrospective chart review of sporadic MTC (sMTC) patients from 12 institutions over the last 29 years. FNAB cytology results were compared to final pathologic diagnoses to calculate FNAB sensitivity. To evaluate the impact of cytology sensitivity for MTC according to current practice and to avoid confounding results by local treatment protocols, changes in treatment patterns over time, and the influence of ancillary findings (e.g., serum calcitonin), therapeutic interventions based on FNAB cytology alone were projected into 1 of 4 treatment categories: total thyroidectomy (TT) and central neck dissection (CND), TT without CND, diagnostic hemithyroidectomy, or observation. RESULTS: A total of 313 patients from 4 continents and 7 countries were included, 245 of whom underwent FNAB. FNAB cytology revealed MTC in 43.7% and possible MTC in an additional 2.4%. A total of 113 (46.1%) patients with surgical pathology revealing sMTC had FNAB findings that supported TT with CND, while 37 (15.1%) supported TT alone. In the remaining cases, diagnostic hemithyroidectomy and observation were projected in 32.7% and 6.1%, respectively. CONCLUSION: FNAB is an important diagnostic tool in the evaluation of thyroid nodules, but the low sensitivity of cytological evaluation alone in sMTC limits its ability to command an optimal preoperative evaluation and initial surgery in over half of affected patients

Multifocality in sporadic medullary thyroid carcinoma: An international multicenter study

Background: Current surgical standard of care in sporadic medullary thyroid carcinoma (sMTC) consists of a minimum of total thyroidectomy with central neck dissection. Some have suggested thyroid lobectomy with isthmusectomy and central neck dissection for patients with sMTC, given their lower frequency of bilateral disease, although this topic has not been thoroughly studied. This study assessed the prevalence of multifocality in sMTC via a large international multi-institutional retrospective review to quantify this prevalence, including the impact of geography, to assess more accurately the risks associated with alternative surgical approaches. Methods: A retrospective chart review of sMTC patients from 11 institutions over 29 years (1983-2011) was undertaken. Data regarding focality, extent of disease, RET germline analysis plus family and clinical history for multiple endocrine neoplasia type 2 (MEN2), and demographic data were collected and analyzed. Results: Patients from four continents and seven countries were included in the sample. Data for 313 patients with documented sMTC were collected. Of these, 81.2% were confirmed with negative RET germline testing, while the remaining 18.8%demonstrated a negative family history and nomanifestations ofMEN2 syndromes other thanMTC. Bilateral disease was identified in 17/306 (5.6%) patients, while multifocal disease was noted in 50/312 (16.0%) sMTC patients. When only accounting for germline negative patients, these rates were not significantly different (5.6% and 17%, respectively). Among them, when disease was unifocal in the ipsilateral lobe and isthmus, bilateral disease was present in 6/212 (2.8%) cases. When disease was multifocal in the ipsilateral lobe or isthmus, then bilateral disease was present in 8/37 (21.6%) cases ( p &lt; 0.001). No geographic differences in focality were identified. Conclusions: The 5.6% prevalence of bilateral foci in sMTC suggests that total thyroidectomy should remain the standard of care for initial surgery, as less complete thyroid surgery may fail to address fully the primary site of disease. Whether ipsilateral tumor focality should be an independent factor determining the need for completion thyroidectomy when sMTC is diagnosed after hemithyroidectomy remains to be determined